Fortress Biotech, Inc.(FBIO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #788 of 2,879 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
FBIO Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Fortress Biotech, Inc. (FBIO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FBIO at 61.8/100 on a 32-signal composite quality model, placing it at rank #788 of 2,879 stocks — the top half of the AI-ranked universe. FBIO scores in the top quartile across balance sheet strength (99.8), free cash flow (97.5), profitability (97.3). Areas of concern include institutional flow (5.9) and revenue scale (12.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Fortress Biotech, Inc. reports quarterly revenue of $16.0M, net income of $110.4M, an operating margin of -48.3%. Top institutional holders of FBIO by reported 13-F value include Opaleye Management, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. FBIO trades on the Nasdaq exchange and files with the SEC under CIK 1429260. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Fortress Biotech, Inc. directly from SEC EDGAR. Fortress Biotech, Inc.'s 13F Pro composite quality score has ranged between 9 and 63 since 2021, currently 61.8 — an improving long-term trajectory across 28 quarterly and live scoring snapshots.
Revenue
Q1 2026
$16.0M
Net Income
Q1 2026
$110.4M
Free Cash Flow
Q1 2026
$203.9M
Operating Margin
Q1 2026
-48.3%
D/E Ratio
Q1 2026
0.23
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+26.5% YoYNet Income
+145.1% YoYOperating Income
-17.1% YoYEPS (Diluted)
Total Assets
-56.7% YoYTotal Debt
+12.2% YoYOp. Cash Flow
+4.2% YoY| Metric | FY 2024 | FY 2020 | FY 2018 | FY 2017 | FY 2016 | FY 2013 |
|---|---|---|---|---|---|---|
| Revenue | $57.7M +26.5% | $45.6M +69.6% | $26.9M +55.9% | $17.2M +4.6% | $16.5M | $0.00 |
| Net Income | $21.0M +145.1% | $-46.5M +44.7% | $-84.1M -25.8% | $-66.9M -21.4% | $-55.1M +54.6% | $-121.3M |
| Operating Income | $-110.4M -17.1% | $-94.3M +21.4% | $-120.0M -33.6% | $-89.8M -36.7% | $-65.7M +43.3% | $-115.8M |
| EPS (Diluted) | $-2.69 | — | — | — | — | — |
| Total Assets | $144.2M -56.7% | $333.4M +136.5% | $141.0M -42.7% | $245.9M +44.1% | $170.7M +69.7% | $100.6M |
| Total Debt | $58.0M +12.2% | $51.7M -38.8% | $84.4M +25.0% | $67.5M +123.5% | $30.2M | — |
| Operating Cash Flow | $-80.2M +4.2% | $-83.7M +15.3% | $-98.8M -21.6% | $-81.3M -77.5% | $-45.8M +40.3% | $-76.7M |
Get alerted when FBIO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Fortress Biotech, Inc. including:
Top Institutional Holders of FBIO
Opaleye Management Inc.
$2.9M1,042,000 shVANGUARD CAPITAL MANAGEMENT LLC
$2.7M966,030 shGEODE CAPITAL MANAGEMENT, LLC
$810.1K290,255 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$793.2K284,300 shNORTHERN TRUST CORP
$641.8K230,053 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$588.0K210,745 shBlackRock, Inc.
$549.9K197,085 shTWO SIGMA INVESTMENTS, LP
$549.1K196,825 shBRIDGEWAY CAPITAL MANAGEMENT, LLC
$508.8K182,368 shCITADEL ADVISORS LLC
$503.0K180,289 sh
| Fund | Value | Shares |
|---|---|---|
| Opaleye Management Inc. | $2.9M | 1,042,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.7M | 966,030 |
| GEODE CAPITAL MANAGEMENT, LLC | $810.1K | 290,255 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $793.2K | 284,300 |
| NORTHERN TRUST CORP | $641.8K | 230,053 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $588.0K | 210,745 |
| BlackRock, Inc. | $549.9K | 197,085 |
| TWO SIGMA INVESTMENTS, LP | $549.1K | 196,825 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $508.8K | 182,368 |
| CITADEL ADVISORS LLC | $503.0K | 180,289 |
More Healthcare Companies
View all Healthcare →Put FBIO on your watchlist
Track score changes the day Fortress Biotech, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is FBIO a good stock to buy?
13F Pro's AI-powered analysis of Fortress Biotech, Inc. (FBIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FBIO are available on the FBIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own FBIO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FBIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Fortress Biotech, Inc.'s investment landscape.